Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 17, 2025
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2023
Regulatory Aspects of Gene Therapy: The Regulatory Life Cycle.
Journal: Hematology/oncology clinics of North America
Published: June 30, 2022
Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 25, 2022
FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 21, 2021
Showing 1-6 of 6
Last Updated: 09/26/2026